Latest filing published 13 May 2014 for Pulmatrix, Inc..
Insider track record
No signal scores available.
Closed purchases
Based on 10 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -14.3%Entry US$4,095.00 · Close at T+365 US$3,510.00
- -12.4%Entry US$4,347.00 · Close at T+365 US$3,807.00
- -4.2%Entry US$4,032.00 · Close at T+365 US$3,861.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Hojabr Alimi: trading record in brief
Hojabr Alimi discloses dealings in 2 companies, chiefly Sonoma Pharmaceuticals, Inc. and Pulmatrix, Inc. We count 24 filings; the first trade dates from 16 November 2007 and the latest from 11 May 2014.
In open-market terms, that means 10 purchases worth €9,733 on one side and 8 sales worth €593k on the other. Sales outweigh purchases by €583k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant and 3 option exercises.
In size, the median ticket on the buying side is €1,050. Ninety days after publication, 10 purchases show a median change of -32.3%, with the price up in 0% of them. Past outcomes like these are no guarantee of what comes next.
The latest filing, published on 13 May 2014, reports a share grant in Pulmatrix, Inc. The most recent open-market purchase was published on 11 December 2012, 5,081 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Hojabr Alimi
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 125,000 shares0Common StockSEC:0001144204-14-029991:0
- 1,000 shares@ US$0.65Common StockSEC:0001019687-12-004487:0Canonical exit: 7 Mar 2013 (T+90)
- 2,000 shares@ US$0.6476Common StockSEC:0001019687-12-004487:1Canonical exit: 7 Mar 2013 (T+90)
- 2,200 shares@ US$0.6489Common StockSEC:0001019687-12-004487:2Canonical exit: 7 Mar 2013 (T+90)
- 100 shares@ US$0.65Common StockSEC:0001019687-12-004487:3Canonical exit: 7 Mar 2013 (T+90)
- 3,000 shares@ US$0.6364Common StockSEC:0001019687-12-004479:0Canonical exit: 10 Mar 2013 (T+90)
- 2,500 shares@ US$0.6393Common StockSEC:0001019687-12-004479:1Canonical exit: 10 Mar 2013 (T+90)
- 1,000 shares@ US$0.6256Common StockSEC:0001019687-12-004452:0Canonical exit: 6 Mar 2013 (T+90)
- 1,000 shares@ US$0.6292Common StockSEC:0001019687-12-004452:1Canonical exit: 6 Mar 2013 (T+90)
- 3,000 shares@ US$0.6329Common StockSEC:0001019687-12-004452:2Canonical exit: 6 Mar 2013 (T+90)
- 4,000 shares@ US$0.6373Common StockSEC:0001019687-12-004452:3Canonical exit: 6 Mar 2013 (T+90)
- 15,000 shares@ US$1.10Common StockSEC:0001209191-10-016420:0
- 15,000 shares@ US$3.16Common StockSEC:0001209191-10-016420:1
- 300,000 shares@ US$0.15Common StockSEC:0001209191-09-040397:0
- 15,000 shares@ US$0.22Common StockSEC:0001209191-09-040397:1
- 150,000 shares@ US$2.2192Common StockSEC:0001209191-09-040397:2
- 165,000 shares@ US$1.9721Common StockSEC:0001209191-09-040397:3
- 13,200 shares@ US$1.05Common StockSEC:0001209191-09-014731:0
- 6,200 shares@ US$1.23Common StockSEC:0001209191-09-014224:0
- 17,800 shares@ US$1.16Common StockSEC:0001209191-09-014224:1
- 7,800 shares@ US$1.14Common StockSEC:0001209191-09-014224:2
- 15,000 shares@ US$5.36Common StockSEC:0001209191-08-017501:0
- 12,500 shares0Common StockSEC:0001209191-07-065153:0
23 of 23 declarations
